US-CONGRESS BILLS-119s4987is: Pharmaceutical Investment Oversight and Accountability Act
The Pharmaceutical Investment Oversight and Accountability Act introduces new transparency and reporting requirements for drug pricing, R&D costs, and manufacturing investments. It also mandates FDA to consider drug shortage risks in approval decisions and imposes stricter cGMP compliance audits for facilities producing controlled substances.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 21, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective 180 days after enactment; reporting deadlines TBD by FDA rulemaking.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New requirements for public disclosure of pricing strategies, R&D costs, and manufacturing investments; FDA must assess shortage risk during drug approval; enhanced cGMP audits for controlled substance facilities; potential DEA quota adjustments based on shortage data.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B)
What you must do
Review current pricing and investment disclosure practices; prepare to submit detailed cost reports; assess supply chain vulnerabilities for shortage risk; ensure cGMP compliance for controlled substance manufacturing.
Deadline
Effective 180 days after enactment; reporting deadlines TBD by FDA rulemaking.
Source: https://www.govinfo.gov/app/details/BILLS-119s4987is
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- US-CONGRESS BILLS-119hr9774ih: To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.
- US-CONGRESS BILLS-119hr9790ih: Modernizing Opioid Treatment Access Act 2.0 of 2026
- US-CONGRESS BILLS-119s4994is: Our Nation’s Supply chain for Healthcare has Over Reliance Elsewhere Act; ONSHORE Manufacturing Act
- FDA Presses Forward on Patient-Focused Drug Development, Releases Final Guidance Focused on Fit-For-Purpose Clinical Outcome Assessments - akingump.com
- CDER’s Framework for Regulatory Advanced Manufacturing Evaluation (FRA - fda.gov